里昂发表报告指，美国总统特朗普关于药品定价的言论重新点燃市场波动。该行认为，美国医疗系统多方支付结构限制政府定价权，任何有意义改革都将影响广泛的利益相关者，使得实际实施高度不确定。
虽然对海外产品高峰销售的担忧正在增加，但美国对中国公司来说仍是增量市场。中国政策环境正变得更加支持性，特别是在药品定价方面更加宽松。该行相信院内药品销售的复苏将是下一个国内周期的主要驱动力，4月数据已显示出积极的改善迹象。
该行增加对领先制药公司在其投资组合分配，包括石药(01093.HK) 、翰森(03692.HK) 及恒瑞医药(600276.SH) 。此外，由于中美贸易冲突缓和，该行增加对药明康德(02359.HK) 的配置。(fc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-12 16:25。) (A股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.